February 6, 2023


Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) – Equity analysts at HC Wainwright lowered their earnings estimates for the first quarter of 2023 for shares of Arrowhead Pharmaceuticals in a research note published on Monday, January 23. HC Wainwright analyst P. Trucchio now expects the biotechnology company to earn $1.34 per share for the quarter, down from its previous estimate of $1.75. HC Wainwright has a buy rating and a price target of $90.00 on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full year earnings is ($0.87) per share. HC Wainwright also provided estimates for Arrowhead Pharmaceuticals’ second quarter 2023 earnings of ($1.09) per share, Q3 2023 earnings of ($1.12) per share, Q4 2023 earnings of ($1 .10) per share, Q4 2023 earnings of ($2.01) per share and FY 2024 earnings of ($3.12). EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($2.08) EPS and FY2027 earnings at ($0.59) EPS.

A number of other research analysts have also issued reports on the stock. B. Riley lowered its price target on Arrowhead Pharmaceuticals from $65.00 to $59.00 and gave the stock a “buy” rating in a report on Wednesday, November. Jefferies Financial Group lowered its target price on shares of Arrowhead Pharmaceuticals from $92.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 29. SVB Leerink lowered its price target on Arrowhead Pharmaceuticals shares to $31.00 from $33.00 and the stock in a report on Tuesday, April 29 January 9, from $64.00 to $55.00. Finally, in a report on Tuesday, November 29, Morgan Stanley lowered its target price on shares of Arrowhead Pharmaceuticals from $41.00 to $37.00 and gave the stock an “equal weight” rating. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target of $59.22.

Arrowhead Pharmaceuticals down 2.8%

NASDAQ:ARWR opened at $32.97 on Wednesday. The company has a market cap of $3.52 billion, a price-to-earnings ratio of -19.62 and a beta of 1.26. The company’s 50-day moving average is $33.92 and the two-hundred-day moving average is $36.49. Arrowhead Pharmaceuticals has a 12-month low of $26.81 and a 12-month high of $56.25.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last released its quarterly earnings data on Monday, November 28th. The biotechnology company reported ($0.81) EPS for the quarter, missing analyst consensus estimates of ($0.57) by ($0.24). The company had revenue of $31.58 million for the quarter, compared to analyst estimates of $107.60 million. Arrowhead Pharmaceuticals had a negative net margin of 71.01% and a negative return on equity of 40.23%.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,200 shares of the stock in a transaction that took place on Monday, January 9th. The shares sold at an average price of $30.00 for a total value of $96,000.00. Following the completion of the sale, the director now owns 28,950 shares of the company, valued at $868,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed at this hyperlink. In other news, Director William D. Waddill sold 3,200 shares of the company’s stock in a transaction that took place Monday, January 9th. The shares were sold at an average price of $30.00 for a total transaction of $96,000.00. Following the completion of the sale, the director now owns 28,950 shares of the company, valued at $868,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Martin Javier San sold 19,500 shares of the company’s stock in a transaction that took place on Monday, November 21st. The stock sold at an average price of $29.99 for a total transaction of $584,805.00. Following the sale, the insider now directly owns 91,500 shares of the company’s stock, valued at approximately $2,744,085. The disclosure for this sale can be found here. Insiders sold 109,966 shares of the company’s stock valued at $4,050,435 in the last 90 days. 3.20% of the shares are owned by company insiders.

Hedge funds rely on Arrowhead Pharmaceuticals

A number of hedge funds recently added to or reduced their stakes in the company. Captrust Financial Advisors increased its stake in Arrowhead Pharmaceuticals by 22.4% during the second quarter. Captrust Financial Advisors now owns 1,201 shares of the $42,000 biotechnology company after buying another 220 shares last quarter. The Arizona State Retirement System increased its stake in Arrowhead Pharmaceuticals by 1.2% in the second quarter. The Arizona State Retirement System now owns 27,151 shares of the biotechnology company, valued at $956,000, after buying another 309 shares last quarter. Private Advisor Group LLC increased its stake in Arrowhead Pharmaceuticals by 2.7% during the third quarter. Private Advisor Group LLC now owns 11,795 shares of the biotechnology company, valued at $390,000, after purchasing an additional 313 shares last quarter. O Shaughnessy Asset Management LLC increased its stake in Arrowhead Pharmaceuticals by 3.5% in the second quarter. O Shaughnessy Asset Management LLC now owns 9,704 shares of the biotechnology company, valued at $342,000, after purchasing an additional 326 shares last quarter. Finally, the Alaska Department of Treasury increased its stake in Arrowhead Pharmaceuticals by 2.2% in the second quarter. The Alaskan Department of Treasury now owns 15,173 shares of the biotechnology company, valued at $534,000, after buying another 330 shares last quarter. Institutional investors and hedge funds own 65.46% of the company’s shares.

About Arrowhead Pharmaceuticals

(received rating)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development of drugs that treat intractable diseases by turning off the genes that cause them. The Company’s pre-clinical drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV and ARO-ENaC.

Further reading

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History and Estimates



Receive daily news and reviews for Arrowhead Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *